Accentia Biopharmaceuticals, Stock Price - ABPI

Best deals to access real time data!
SMALL CAP PRO
Monthly Subscription
for only
$43.59
ULTIMATE TRADER
Monthly Subscription
for only
$65.99
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$30.00
VAT not included
Company Name Stock Ticker Symbol Market Type ISIN
Accentia Biopharmaceuticals, Inc. ABPI Other OTC Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded DELAYED
  +0.00 +0.00% 0.0001 - - - 0.0001 02:05:05
Last Trade Time Type Quantity Stock Price Currency
- - - USD

Accentia Biopharmaceuticals, Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 8.98k 89.76M $ -4.32M - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Accentia Biopharmaceuticals, Inc. News

Date Time Source News Article
1/15/201612:58Edgar (US Regulatory)Revocation of Exchange Act Registration Pursuant to Section..

Historical ABPI Price Data

Period † Open High Low VWAP Min Vol Max Vol Avg. Daily Vol [m] Change %
1 Week0.000.000.000.0000000--
1 Month0.000.000.000.0000000--
3 Months0.000.000.000.0000000--
6 Months0.000.000.000.0000000--
1 Year0.00010.0010.000.0000400162k21k0.00-
3 Years0.00310.0270.000.000006M126k-0.00-96.77%
5 Years0.340.570.000.000006M121k-0.34-99.97%

Accentia Biopharmaceuticals, Inc. Description

Accentia Biopharmaceuticals, Inc. is engaged in the business of commercializing patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications.

Accentia is advancing a portfolio of potential blockbuster drug candidates which target multi-billion dollar market opportunities. These late-stage products include: BiovaxID., a novel anti-idiotype cancer vaccine for the treatment of B-cell malignancies including indolent follicular non-Hodgkin's lymphoma; Revimmune(c), a novel ultra-high-dose formulation of a previously approved chemotherapeutic agent expected to show utility in the treatment of up to 80 autoimmune diseases, with an initial focus on multiple sclerosis; and SinuNase(c), a novel formulation of a previously approved anti-fungal for the topical, intranasal treatment of chronic sinusitis.

Additionally, Accentia's wholly-owned subsidiary, Analytica International, markets pharmaceutical consulting services.

Accentia's interest in BiovaxID is based on its majority ownership stake in Biovest International, Inc. and Accentia also maintains a royalty interest in Biovest's biologic products. Accentia is a portfolio company of the Hopkins Capital Group.
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:33 V: D:20161206 14:13:05